C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use

Patent metadata

Field	Value
Publication number	US-11008338-B2
Application number	US-202016821001-A
Country	US
Kind code	B2
Filing date	Mar 17, 2020
Priority date	Feb 11, 2016
Publication date	May 18, 2021
Grant date	May 18, 2021

Abstract

In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker, including compounds Formula (I):

or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R 1 , R 2 , R 3 , R A , ring A, m, n, -L 1 -, ring B, R B , and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

First claim

What is claimed is:

1. A compound, or a pharmaceutically acceptable salt thereof, said compound having the structural Formula (I):

or a tautomer thereof having the structural Formula (I′):

or pharmaceutically acceptable salt thereof, wherein:
ring C is selected from the group consisting of tetrahydrofuranyl and tetrahydropyranyl, wherein 1 or 2 of the ring carbon atoms having two available substitutable hydrogen atoms of said tetrahydrofuranyl and tetrahydropyranyl rings are optionally independently replaced with a —C(R C1 R C2 )— group,
wherein R C1 and R C2 are each independently selected from the group consisting of H, halogen, —CO 2 —(C 1 -C 6 -alkyl), alkyl, cycloalkyl, -alkyl-cycloalkyl, heterocycloalkyl, -alkyl-heterocycloalkyl, aryl, -alkyl-aryl, heteroaryl, and -alkyl-heteroaryl,
wherein each said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl of R C1 and R C2 are optionally substituted with one or more R 3 , and
wherein 1 to 2 non-adjacent, non-terminal carbon atoms in each said alkyl of R C1 and R C2 are optionally independently replaced with —O—, —NH—, —N(C 1 -C 6 -alkyl)-, —S—, —S(O)—, or —S(O) 2 —,

or, alternatively, wherein said R cl and R C2 of one said —C(R C1 R C2 )— group are taken together with the carbon to which they are attached form a spirocyclic ring consisting of from 3 to 6 carbon atoms,
wherein 1 of said carbon atoms may be replaced with —O—, —NH—, —N(C 1 -C 6 -alkyl)-, —N(C 1 -C 6 -haloalkyl)-, —S—, —S(O)—, or —S(O) 2 —, and
wherein 1 to 2 of the carbon atoms of said spirocyclic ring may be optionally and independently substituted with 1 to 2 fluorine, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, or —CH 2 O—(C 1 -C 6 -alkyl);
R 1 is selected from the group consisting of H, halogen, and alkyl,
wherein said alkyl is optionally substituted with one or more fluorine, and
wherein 1 to 2 non-adjacent, non-terminal carbon atoms in said alkyl are optionally independently replaced with —O—, —NH—, —N(alkyl)-, —S—, —S(O)—, or —S(O) 2 —;
R 2 and R 3 are each independently selected from the group consisting of H, halogen, alkyl, cycloalkyl, -alkyl-cycloalkyl, heterocycloalkyl, -alkyl-heterocycloalkyl, aryl, -alkyl-aryl, heteroaryl, and alkyl-heteroaryl,
wherein each said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl of R 2 and R 3 are optionally substituted with one or more R 4 , and
wherein 1 to 2 non-adjacent, non-terminal carbon atoms in each said alkyl of R 2 and R 3 are optionally independently replaced with —O—, —NH—, —N(C 1 -C 3 -alkyl)-, —S—, —S(O)—, or —S(O) 2 —,
or, alternatively, R 2 and R 3 are taken together with the carbon to which they are attached form a spirocyclic ring consisting of from 3 to 6 carbon atoms,
wherein 1 of said carbon atoms may be replaced with —O—, —NH—, —N(C 1 -C 3 -alkyl)-, —N(C 1 -C 3 -haloalkyl)-, —S—, —S(O)—, or —S(O) 2 —, and
wherein 1 to 2 of the carbon atoms of said spirocyclic ring may be optionally independently substituted with 1 to 2 fluorine, C 1 -C 3 -alkyl, C 1 -C 3 -haloalkyl, or —CH 2 O—(C 1 -C 3 -alkyl);
ring A is selected from the group consisting of aryl and heteroaryl;
m is 0 or more, with the proviso that the value of m does not exceed the number of available substitutable hydrogen atoms on ring A;
each R A (when present) is independently selected from the group consisting of halogen, oxo, —OH, —CN, alkyl, —O-alkyl, and cycloalkyl,
wherein said alkyl, —O-alkyl, and cycloalkyl of R A are each optionally independently unsubstituted or substituted with one or more fluorine, and wherein 1 to 2 non-adjacent, non-terminal carbon atoms in said alkyl and —O-alkyl are optionally independently replaced with —O—, —NH—, —N(C 1 -C 3 -alkyl)-, —S—, —S(O)—, or —S(O) 2 —;
n is 1;
-L 1 represents a bond or a divalent moiety selected from the group consisting of —O—, —CH 2 O—, —CH(CH 3 )O—, —CH(CF 3 )O—, and —CH(CHF 2 )O—;
ring B is selected from the group consisting of aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, with the provision that when L 1 is —O— or —CH 2 O—, then ring B is other than cycloalkyl;
p is 0 or more, with the proviso that the value of p does not exceed the number of available substitutable hydrogen atoms on ring B; and
each R B (when present) is independently selected from the group consisting of halogen, oxo, —OH, —CN, —SF 5 , —OSF 5 , —OR B1 , —SR B1 , alkyl, alkenyl, alkynyl, cycloalkyl, -alkyl-cycloalkyl, heterocycloalkyl, -alkyl-heterocycloalkyl, aryl, and heteroaryl,
wherein said each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl of R B are each optionally independently unsubstituted or substituted with one or more groups independently selected from R 4 , and wherein 1 to 2 non-adjacent, non-terminal carbon atoms in said alkyl are optionally independently replaced with —O—, —NH—, —N(alkyl)-, —S—, —S(O)—, or —S(O) 2 —;
each R B1 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, -alkyl-cycloalkyl, heterocycloalkyl, and alkyl-heterocycloalkyl,
wherein each said alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl, of R B1 is unsubstituted or optionally substituted with one or more fluorine, and
wherein 1 to 2 non-adjacent, non-terminal carbon atoms in said alkyl are optionally independently replaced with —O—, —NH—, —N(C 1 -C 6 -alkyl)-, —S—, —S(O)—, or —S(O) 2 —;
each R 4 (when present) is independently selected from the group consisting of halogen, —OH, —CN, C 1 -C 6 -alkyl, —(C 1 -C 6 -alkyl)-OH, —O—(C 1 -C 6 -alkyl), cycloalkyl, —(C 1 -C 6 -alkyl)-cycloalkyl, —O-cycloalkyl, —O—(C 1 -C 6 -alkyl)-cycloalkyl, heterocycloalkyl, —(C 1 -C 6 -alkyl)-heterocycloalkyl, —O-heterocycloalkyl and —O—(C 1 -C 6 -alkyl)-heterocycloalkyl,
wherein each said C 1 -C 6 -alkyl, cycloalkyl, and heterocycloalkyl are optionally substituted with one or more halogen,
and wherein 1 to 2 non-adjacent, non-terminal carbon atoms in each said C 1 -C 6 -alkyl is optionally independently replaced with —O—, —NH—, —N(C 1 -C 3 -alkyl)-, —S—, —S(O)—, or —S(O) 2 —.

2. A compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein:
ring C is selected from the group consisting of:

3. A compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein:

ring C is.

4. A compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein:
R 2 and R 3 are each independently selected from the group consisting of methyl, —CHF 2 , and —CH 2 F, cyclopropyl, phenyl, pyridyl, and tetrahydropyranyl,
wherein each said cyclopropyl, phenyl, pyridyl, tetrahydropyranyl of R 2 and R 3 are unsubstituted or substituted with one or two groups independently selected from the group consisting of fluorine, methyl, ethyl, cyclopropyl, and —OCH 3 ,
wherein each said methyl, ethyl, cyclopropyl, and —OCH 3 is each optionally substituted with from 1 to 3 fluoro groups.

5. A compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautom

Assignees

• Merck Sharp & Dohme

Inventors

• Wu Wen-Lian
• Cumming Jared N
• Taoka Brandon M
• Dai Xing

Classifications

• C07D513/10

  Spiro-condensed systems · CPC title

• C07D513/04

  Ortho-condensed systems · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07D513/02 Primary

  in which the condensed system contains two hetero rings · CPC title